Last year, Danone unveiled a high-protein drinkable yoghurt for the US market under its Oikos label, which is said to help consumers build and retain muscle mass during weight loss
Eli Lilly published the results of its ATTAIN-1b trial for obesity in September 2025 7 , which compared orforglipron to placebo in more than 3,100 adults without diabetes, with a BMI of 30+ or 27-30 with an obesity-related complication including hypertension, dyslipidaemia, cardiovascular disease or obstructive sleep apnoea and a history of at least one patient-reported unsuccessful dietary effort to lose body weight, who have tried unsuccessfully to lose weight with diet alone
What did the expert panel recommend for GLP-1 use in type 1 diabetes
Keep taking it as prescribed and be sure to let your clinician know about all the medications you're taking
A convenient synthesis of R-()-carnitine from R-()-epichlorohydrin
The Liposomal Advantage Liposomal delivery is a sophisticated system designed to support absorption at the cellular level
